GlaxoSmithKline Withdraws Patent Applications For Antiretrovirals
GlaxoSmithKline recently withdrew the patentapplications for its antiretroviral drugs Abacavir and Trizivir in
Abacavir is a second-line antiretroviral used to treat people living withHIV/AIDS who have developed resistance to first-line drugs. Trizivir is atriple-combination antiretroviral used for first- and second-line treatments,the Times reports. Both antiretrovirals are on the World Health Organization's recommended list of drugs for HIV treatments, the Timesreports. Some Indian generic drug companies -- including Cipla, Ranbaxy Laboratories and Hetero Drugs -- already market one or both drugsin the country. GSK declined to comment on the status of the applications. AGSK spokesperson said the company does "not comment on specific patentapplications. However, as part of our policy, routine reviews of our patentapplications are undertaken on a regular basis."
An unnamed source said GSK's move is the result of Swiss pharmaceutical companyNovartis's failed challenge to a section of thecountry's Patents Act that aims to restrict certain kinds of patents (Singh, EconomicTimes, 12/7).
Reprinted with permission from kaisernetwork.org. You can view theentire Kaiser DailyHIV/AIDS Report, search the archives, and sign up for email delivery at kaisernetwork.org/email . The Kaiser Daily HIV/AIDS Report ispublished for kaisernetwork.org, a free service of The Henry J. Kaiser FamilyFoundation.